Dermatology and Therapy (Sep 2023)
Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
Abstract
No abstracts available.Keywords
Dermatology and Therapy (Sep 2023)